Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Here is the link
https://aimchaos.files.wordpress.com/2022/04/avacta-group-precision-platform.pdf
The language used in Point Biopharma's pre | CISION™ product pipeline is very exciting too:
POINT's CanSEEK™ has been sub-licensed from both Bach Biosciences and Avacta Life Sciences, which has branded the technology as pre | CISION™ (an Avacta trademark).
Toxicity caused by off-target delivery is a longstanding concern of cancer therapies.
Developed by Dr. William Bachovchin of Tufts University, POINT’s CanSEEK™ technology aims to minimize radiopharmaceutical toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety, such as its ligand, after it has encountered FAP-a in the tumor microenvironment (TME). FAP-a is highly expressed on a wide range of solid tumors, but in very low quantities or absent altogether in healthy tissues.
The intent of CanSEEK™ is to minimize the toxicity caused by off-target delivery. At first, CanSEEK™ prevents the radiopharmaceutical from bonding to receptors on cells. When the radiopharmaceuticals enter the TME, the radiopharmaceuticals targeting moiety is re-activated, enabling it to once again bond to receptors on cancer cells.
CanSEEK™ has the potential to make treatments even more precise, expanding their therapeutic index, and enabling the use of new, more powerful medical isotopes.
https://www.pointbiopharma.com/our-products/pipeline/canseek
Nice video to explain where AVA 3396 might be headed
https://www.myeloma.org.uk/videos/proteasome-inhibitor-drugs/
TED talk - What is Chemotherapy? We all know what it is but this video really crystallises what Avacta are trying to achieve.
https://www.youtube.com/watch?v=RgWQCGX3MOk
The info at the bottom of the RNS has changed AGAIN.
Moderna are back in and Point Biopharma information has changed too.
Today's RNS
Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with ModernaTX, Inc. (formerly Moderna Therapeutics Inc.), a multi-target deal with LG Chem worth up to $400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators and a collaboration with Point Biopharma to develop radiopharmaceuticals based on the pre|CISION™ platform. Avacta continues to actively seek to license its proprietary platforms in a range of therapeutic areas.
Wednesdays RNS
Avacta has established drug development partnerships with pharma and biotech, including a multi-target deal with LG Chem worth up to $400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer® immune-modulators and a recent license agreement with Point Biopharma for them to develop radiopharmaceuticals based on the pre|CISION™ platform.
Recent previous RNS:
Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.
The Affimer® platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal's immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture.
Avacta's pre|CISION™ targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful anti-cancer treatments.
The Group comprises two divisions: The therapeutics development activities are based in London and Cambridge, UK and the Group is generating near-term revenues from Affimer reagents for diagnostics, bioprocessing and research, through a separate diagnostics business unit based in Wetherby, UK.
Avacta's Diagnostics Division is developing an in-house pipeline of Affimer-based diagnostic assays, including the AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test, and works with partners world-wide to develop bespoke Affimer® reagents for third party products.
Avacta's Therapeutics Division is working to deliver a more tolerable and durable treatment response for oncology patients who do not respond to existing immunotherapies. By combining its two proprietary platforms the Group is building a wholly owned pipeline of clinically differentiated cancer therapies, aiming to extend the therapeutic benefits to all cancer patients. In 2021 Avacta transitioned to become a clinical stage biopharmaceutical company, commencing a phase I first-in-human, open label, dose-escalation and expansion study of AVA6000, a pro-doxorubicin, the Group's lead pre|CISION™ prodrug, in patients with locally advanced or metastatic selected solid tumours.
Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with ModernaTX, Inc. (formerly Moderna Therapeutics Inc.), a multi-target deal with LG Chem worth up to $400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators and a collaboration with Point Biopharma to develop radiopharmaceuticals based on the pre|CISION™ platform. Avacta continues to actively seek to license its proprietary platforms in a range of therapeutic areas.
I just wanted to point out that there are a number of changes to the text at the bottom of this mornings RNS compared to other recent RNS. I know it is a constantly evolving company description but the subtle changes make for very interesting reading.
Todays RNS:
Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.
The Affimer® platform is an alternative to antibodies and is derived from a small human protein. Affimer technology has been designed to address many of the negative issues of antibodies, principally: the time taken to generate new antibodies, the reliance on an animal's immune response; poor specificity in many cases; in addition to, the complexity and high cost of manufacture. Despite these shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, which are worth in excess of $100bn.
Avacta's pre|CISION™ targeted chemotherapy platform is designed to selectively release active chemotherapy in FAP rich tumour tissue to limit the systemic exposure that causes damage to healthy tissues, and thereby aims to improve the overall safety and therapeutic potential of these powerful anti-cancer treatments.
The Avacta Group comprises two divisions: The therapeutics development activities are based in London and Cambridge, UK and a separate diagnostics business unit is based in Wetherby, UK. The Group is generating near-term revenues from Affimer® reagents for diagnostics, bioprocessing and research.
Avacta's Diagnostics Division is developing an in-house pipeline of Affimer-based diagnostic assays, including the AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test, and works with partners world-wide to develop bespoke Affimer® reagents for third party products.
Avacta's Therapeutics Division is working to generate more tolerable and durable treatments for oncology patients who do not respond to existing therapies. By combining its two proprietary platforms the Group is building a wholly owned pipeline of clinically differentiated cancer therapies. In 2021 Avacta transitioned to become a clinical stage biopharmaceutical company, when it commenced a phase I trial in patients with locally advanced or metastatic selected solid tumours. The study was a first-in-human, open label, dose-escalation and expansion study of the Group's lead pre|CISION™ prodrug, AVA6000 (a pro-doxorubicin).
Avacta has established drug development partnerships with pharma and biotech, including a multi-target deal with LG Chem worth up to $400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators and a recent license agreement with Point Biopharma for them to develop radiopharmaceuticals based on the pre|CISION™ platform.
Professor Callum Semple from the Uni of Liverpool is on the BBC2 news discussing LFTs for the 7 day non quarantine option to be voted for this afternoon - excellent discussion and worth a watch. Watch from 9.19am
D0berman here is the link and fast forward to 3h 19 mins
https://www.bbc.co.uk/iplayer/episode/m000ywss/breakfast-14082021
https://www.bbc.co.uk/iplayer/live/bbcone
9.15 am the two scientists, Dr Linda Bauld and Dr Chris Smith. Listen from 9.19 - I guarantee that you will be screaming at your TV or computer!
Jerry Hunt in parliament asking Naphim Zahawi a great question. NZ confirms that from 16th August
everyone will be allowed to not self isolate but take 7 days of LFT and one neg PCR test.
https://twitter.com/Jeremy_Hunt/status/1417171748072665093
Just found this on Twitter
Care homes study from the Liverpool Community Testing pilot
Reports that enhanced lateral flow testing strategies in care homes are associated with poor adherence and were insufficient to prevent #COVID-19 outbreakshttps://twitter.com/adamgordon1978/status/1417155481441812491
I think they need a better test that is less invasive and faster to use.
Here are the articles to support the daily testing for Boris.
https://www.bbc.co.uk/news/uk-57877373
or
https://www.mirror.co.uk/news/politics/breaking-boris-johnson-dodges-self-24559242?utm_source=facebook.com&utm_medium=social&utm_campaign=mirror_main&fbclid=IwAR1y-DFw4RoO3kRs1IEFzgq2y3sLLfUduEBGCaV-8tDyVkVKRGXvzmgyKGM
Yes he has
https://www.bbc.co.uk/news/uk-57625508
This is their article from their website.
https://www.medicaldetectiondogs.org.uk/covid-19-detection-dogs/?fbclid=IwAR2Ahm2gDG83i8QsNP8sTSoFELRJT34yC7UxqTrPujrfR8xMSu7q5DiYgp8